IMMU-114 is a humanized antibody targeting HLA-DR, which inhibits human responses to bovine cells, used in malignant tumor research.

IMMU-114 can effectively inhibit human cell response to cattle. The mechanism involves direct inhibition of interactions between Class II human leukocyte antigen DR Positive cells and CD4 (+) T cells, as well as indirect inhibition of Th1 cytokine production. [1]
In allogeneic MLRs, IMMU-114 treatment inhibited T cell proliferation and reduced CD25 (+) alloreactive T cells. [2]

In seven human disease models (acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), multiple myeloma (MM), acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and melanoma), IMMU-114 has anti-tumor effect. [3]

Human

Monoclonal

Unconjugated